PARP抑制剂用于前列腺癌：在PROfound，PROpel和TALAPRO-2中纠缠不清。
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.
发表日期：2023 Apr 20
作者：
Nick Beije, Wassim Abida, Emmanuel S Antonarakis, Elena Castro, Ronald de Wit, Karim Fizazi, Silke Gillessen, Maha Hussain, Joaquin Mateo, Michael J Morris, David Olmos, Oliver Sartor, Adam Sharp, Christopher J Sweeney, Johann S de Bono
来源：
EUROPEAN UROLOGY
摘要：
在疾病生物学的基础上，PARP 和雄激素受体信号抑制剂的组合最好保留给我们预期可以获得总体生存受益的病例。迄今的数据应该鼓励我们进行更多而不是更少的 DNA 修复缺陷测试。版权所有©2023年欧洲泌尿科学会。由 Elsevier B.V. 发布。保留所有权利。
The combination of PARP and androgen receptor signalling inhibitors is best reserved for cases for which we expect an overall survival benefit on the basis of disease biology. The data to date should encourage us to perform more, not less, testing for DNA repair defects.Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.